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The burden of C. difficile infection increases (10), and C. difficile is considered by the US CDC as an 70 urgent threat (11). C. difficile pathophysiology is related to the perturbation of the intestinal 71 microbiota and its metabolism, which allows C. difficile spores to germinate and colonize the gut, and 72 cytotoxic toxins to be released. Various animal models have been developed to delineate the 73 pathophysiology of C. difficile infection (12); including the golden Syrian hamster model (13) . In this 74 model, hamsters treated with antibiotics and colonized by C. difficile are highly susceptible to lethal 75 infection, and the degree of susceptibility to develop infection varies between classes of antibiotics 76 (14, 15) .
77
There is however no precise and quantitative analysis of the relationship between antibiotics effect 78 on the global bacterial diversity within the intestinal microbiota and the development of severe C. 79 difficile infection. Yet diversity is the first descriptor of the structure of a community and is believed 80 to be a major determinant of its dynamics. The analysis of complex bacterial communities was made 81 possible by the development of efficient sequencing technologies applied to 16S rRNA genes (16).
82
These genes are found in all bacterial species and contain regions which are highly conserved and 83 others which are highly variable in sequence and can be used as molecular fingerprints. Several 84 metrics are available for measuring diversity in bacterial communities. Alpha-diversity refers to 85 within-sample diversity and is usually analyzed using the number (richness) and the distribution 86 (evenness) of bacterial taxa observed within a single population, e.g., the Shannon diversity index, 87 number of observed operational taxonomic units (OTUs) and the Chao1 index (17, 18). Beta-diversity, 88 which refers to diversity between samples, measures the distance between pairs of samples, e.g.,
89
UniFrac distances based on bacterial taxonomy and Bray-Curtis dissimilarity index (19, 20) .
90
However whether the intensity of the dysbiosis, as it can be reflected by the variations of these 91 global indices is quantitatively related to the occurrence of C. difficile infection has not be explored 92 so far. This is important for a better understanding of the pathophysiology of C. difficile infection and 93 to determine whether various degrees of dysbiosis are associated with various degrees of risk of C.
94
difficile infection. Here we explored this relationship in an animal model of C. difficile infection in 95 hamsters. We had previously showed that DAV131A, a charcoal-based adsorbent with the same 96 principle of action than the DAV132 product which has recently proven to be highly effective to 97 reduce fecal antibiotic concentrations and dysbiosis in human volunteers treated with moxifloxacin 98 (21), reduced mortality through a decrease of fecal antibiotic concentrations in a hamster model of 99 lethal moxifloxacin-induced C. difficile colitis (22). We induced various degrees of dysbiosis by 100 treating hamsters either with clindamycin or moxifloxacin, which have different antibacterial spectra 101 but are both highly associated with the occurrence of C. difficile infection, and we modulated 102 intestinal antibiotic concentrations by using various doses of DAV131A.
103

Results
104
In order to further analyze the pathophysiology of severe C. difficile colitis, we treated hamsters with 105 either moxifloxacin (total number of 70 animals) or clindamycin (total of 60 animals) for 5 days in 2 106 separate studies with similar designs (see Figure 1 ). Some groups received various doses of DAV131A 107 given orally bis in die (bid) concomitantly with the antibiotic and for an additional 3 days after 108 (corresponding to a total of 8 days). All hamsters were challenged with 10 4 spores of a toxigenic C.
109
difficile strain on the 3 rd day of antibiotic treatment. We analyzed the quantitative relationship subsequent death from infection.
112
Among antibiotic-treated animals, 10 (12.5%) died in the moxifloxacin study, and 28 (40.6%) in the 113 clindamycin study. One hamster from one of the control groups died during the acclimation period, 114 but none did after the beginning of antibiotic treatment. Significant differences in mortality rates 115 were observed between groups which received various doses of DAV131A in addition to the 116 antibiotic (p<10 -11 in the moxifloxacin study and p<10 -10 in the clindamycin study). In both studies, all 117 hamsters treated with antibiotic + DAV131A placebo died. In the moxifloxacin study, all hamsters 118 receiving 200 mg/kg DAV131A bid and greater survived, whereas in the clindamycin study, there was 119 a dose-dependent reduction of mortality from 90% at 300 mg/kg DAV131 bid to 100% survival 120 reached at 750 mg/kg DAV131 bid and above. Full results are presented in Table 1 and Figure 2 .
121
Fecal concentration of active antibiotics, as measured by a microbiological assay, decreased as 122 expected with increasing doses of DAV131A (p<10 -9 in the moxifloxacin study and p<10 -4 in the 123 clindamycin study). These concentrations were significantly lower in hamsters which survived than in 124 those which died during the study (p=0.00025 in the moxifloxacin study and p<10 -6 in the clindamycin 125 study, see Table 2 ).
126
The structure of the bacterial intestinal microbiota was studied by 16S rRNA gene profiling using (Table 1 and Supplementary Table 1 ).
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Indeed, loss of diversity increased with increasing concentrations of active antibiotic in feces, 
162
As these two indices were highly predictive of mortality, we further studied them by determining 163 their optimal cut-off value best discriminating between death and survival by D 16 using the Youden 
252
In the clindamycin study, 60 animals were treated with clindamycin and 10 were left untreated.
253
Groups of 10 antibiotic-treated animals were constituted according to the DAV131A unit dose 
327
The best cut-off value for discriminating between hamsters which died and which survived at D 16 was 328 determined as the value allowing the maximization of both sensitivity and specificity, using the 329 Youden index (38) and its 95% confidence interval. In the frame of the present study, sensitivity 330 represents the probability of change of diversity between D 0 and D 3 being higher than a cut-off value 331 in hamsters who will die by D 16 , and specificity is the probability of the change of diversity being 332 lower than a cut-off value in hamsters who will survive until D 16 . The Youden index is computed as 333 sensitivity + specificity -1, and ranges between -1 and 1. A logistic model was then used to 334 determine the diversity index values required to reduce mortality to various rates ranging from 1% to 335 10%.
Data are presented as number of observations n (%) or median (min; max). All tests were 2-sided 337 with a type-I error of 0.05. All analyses were performed using R software v3. Male Syrian Golden hamsters were treated with moxifloxacin (MXF, n=70) or clindamycin (CLI, n=60) once a day (OAD) by the subcutaneous route for 5 days and received various doses of DAV131A bis in die (BID) by the oral route for 8 days, that would result in the exposition of the microbiota to various antibiotic concentrations and different bacterial environment. Toxigenic strain of C. difficile UNT103-1 was inoculated at D3. Fecal samples were obtained just before the beginning of treatment, and at the 3 rd treatment day. Microbiota analysis was performed by 16S rRNA gene sequencing on both samples, and fecal concentration of active antibiotic was determined at D3 by microbiological assay. Survival was monitored up to D16. The boxes present the 25 th and 75 th percentiles and the horizontal black bar report the median value, while whiskers report 5 th and 95 th percentiles. 
